Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma

Published:2015-09-19 Issue:12 Volume:94 Page:2043-2053
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Nakamura Nobuhiko,Hara Takeshi,Shibata Yuhei,Matsumoto Takuro,Nakamura Hiroshi,Ninomiya Soranobu,Kito Yusuke,Kitagawa Junichi,Kanemura Nobuhiro,Goto Naoe,Shiraki Makoto,Miyazaki Tatsuhiko,Takeuchi Tamotsu,Shimizu Masahito,Tsurumi Hisashi

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-015-2499-4.pdf

Reference55 articles.

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon

2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242. doi: 10.1056/NEJMoa011795

3. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O’Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23(22):5027–5033. doi: 10.1200/JCO.2005.09.137

4. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial G (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379–391. doi: 10.1016/S1470-2045(06)70664-7

5. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329(14):987–994. doi: 10.1056/NEJM199309303291402

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Vitamin D and Skeletal Muscle Mass on Prognosis of Patients with Diffuse Large B-Cell Lymphoma;Nutrients;2024-08-11

2. Association between skeletal muscle mass and treatment response in patients with diffuse large B-cell lymphoma;Leukemia & Lymphoma;2024-08-02

3. Sarcopenia is a prognostic factor in lymphoma patients: a systematic review and meta-analysis;Leukemia & Lymphoma;2024-07-31

4. Incorporating advanced interpretability and expanded feature inclusions in predictive models for sarcopenia: Future directions;Geriatrics & Gerontology International;2024-07-15

5. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy decreases lean body mass and appendicular skeletal muscle mass index even until one year after the final treatment in patients with B-cell non-Hodgkin lymphoma;Journal of Chemotherapy;2024-07-11